Concepedia

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier, R. Delva, Gwénaëlle Gravis, Frédéric Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houédé, Christine Théodore,

The Lancet Oncology · 2015 · 238 citations · 25 references

References

25

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

A Multiple Testing Procedure for Clinical Trials

Peter C. O’Brien, Thomas R. Fleming · Biometrics · 1979 · 3.3K citations

Public Health, Biostatistics, Evidence-based Practice +13

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference

Mack Roach, Gerald E. Hanks, Howard D. Thames et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 2.7K citations

Medicine, Radiation Oncology, Urology +14

Duration of Androgen Suppression in the Treatment of Prostate Cancer

M. Bolla, Theodorus M. de Reijke, Geertjan van Tienhoven et al. · New England Journal of Medicine · 2009 · 966 citations · Full text

Medicine, Oncology, Urology +14

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

M. Bolla, Geertjan van Tienhoven, Padraig Warde et al. · The Lancet Oncology · 2010 · 944 citations

Medicine, Oncology, Radiation Oncology +17